Quick Takeaways
- James E. Flynn filed SCHEDULE 13G/A for BioCryst Pharmaceuticals, Inc. Common Stock (BCRX).
- Disclosed ownership: 6.8%.
- Date of event: 31 Dec 2025.
James E. Flynn - 31 Dec 2025 SCHEDULE 13G/A Report for BioCryst Pharmaceuticals, Inc. Common Stock (BCRX)
- Filing Manager
- James E. Flynn
- Reporting Manager
- Deerfield Mgmt, L.P.
- Symbol
- BCRX
- Shares outstanding
- 210,587,372 shares
- Disclosed Ownership
- 14,341,000 shares
- Ownership
- 6.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Feb 2026, 14:17:01 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 19 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"James E. Flynn disclosed 6.8% ownership in BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 19 Sep 2025.
- Current filing was accepted on 12 Feb 2026, 14:17.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deerfield Mgmt, L.P. | 6.8% | 14,341,000 | 0 | 14,341,000 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact | |
| Deerfield Management Company, L.P. | 6.8% | 14,341,000 | 0 | 14,341,000 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact | |
| Deerfield Partners, L.P. | 6.8% | 14,341,000 | 0 | 14,341,000 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact | |
| James E. Flynn | 6.8% | 14,341,000 | 0 | 14,341,000 | /s/ Jonathan Isler | Jonathan Isler, Attorney-In-Fact |